These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 18491918

  • 1. Inhalable siRNA: potential as a therapeutic agent in the lungs.
    Durcan N, Murphy C, Cryan SA.
    Mol Pharm; 2008; 5(4):559-66. PubMed ID: 18491918
    [Abstract] [Full Text] [Related]

  • 2. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP.
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [Abstract] [Full Text] [Related]

  • 3. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD, Huang L.
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [Abstract] [Full Text] [Related]

  • 4. RNA interference strategies as therapy for respiratory viral infections.
    DeVincenzo JP.
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S118-22. PubMed ID: 18820571
    [Abstract] [Full Text] [Related]

  • 5. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D, Zimmer A.
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [Abstract] [Full Text] [Related]

  • 6. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S, Benter I.
    Adv Drug Deliv Rev; 2007 Mar 30; 59(2-3):164-82. PubMed ID: 17481774
    [Abstract] [Full Text] [Related]

  • 7. siRNA delivery systems for cancer treatment.
    Oh YK, Park TG.
    Adv Drug Deliv Rev; 2009 Aug 10; 61(10):850-62. PubMed ID: 19422869
    [Abstract] [Full Text] [Related]

  • 8. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D, Losert D, Wacheck V.
    Clin Sci (Lond); 2006 Jan 10; 110(1):47-58. PubMed ID: 16336204
    [Abstract] [Full Text] [Related]

  • 9. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S, Zhao B, Jiang H, Wang B, Ma B.
    J Control Release; 2007 Oct 18; 123(1):1-10. PubMed ID: 17716771
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A.
    Curr Opin Mol Ther; 2007 Aug 18; 9(4):345-52. PubMed ID: 17694447
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficient and targeted delivery of siRNA in vivo.
    Shim MS, Kwon YJ.
    FEBS J; 2010 Dec 18; 277(23):4814-27. PubMed ID: 21078116
    [Abstract] [Full Text] [Related]

  • 14. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A, Vlassov AV.
    Med Sci Monit; 2006 Apr 18; 12(4):RA67-74. PubMed ID: 16572063
    [Abstract] [Full Text] [Related]

  • 15. Small interfering RNA for experimental cancer therapy.
    Tong AW, Zhang YA, Nemunaitis J.
    Curr Opin Mol Ther; 2005 Apr 18; 7(2):114-24. PubMed ID: 15844618
    [Abstract] [Full Text] [Related]

  • 16. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK, Hajeri PB.
    Drug Discov Today; 2009 Sep 18; 14(17-18):859-65. PubMed ID: 19540929
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic application of RNA interference for hepatitis C virus.
    Watanabe T, Umehara T, Kohara M.
    Adv Drug Deliv Rev; 2007 Oct 10; 59(12):1263-76. PubMed ID: 17822803
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.